Adverse effects of severe infections and invasive fungal infections may also occur, and treatment should not be initiated during any active infections. Patients with hepatitis b virus (HBV) are at risk for HBV reactivation. Patients with underlying congestive heart failure (CHF) receiving golimumab may also have worsening CHF symptoms. New-onset CHF may also occur. Lupus-like syndrome and hypersensitivity reactions such as anaphylaxis may also transpire. Worsening or new-onset demyelinating disorders have also been reported.

- Upper respiratory tract infection (URTI): nasopharyngitis, pharyngitis, laryngitis, and rhinitis (13 to 16%)

- Sinusitis (2%)

- Bronchitis (2%)

- Viral infections (4 to 5%)

- Bronchitis (2 to 3%)

- Injection site reaction: pain, redness, urticaria, induration, bruising, pruritus, irritation (3 to 6%)

- Elevated liver enzymes: alanine aminotransferase (4%), aspartate aminotransferase (3%)

- Hypertension (3%)

- Dizziness (2%)

- Paresthesia (2%)

- Constipation (1%)

- Pyrexia (2%)

- Leukopenia (1%)

- Superficial fungal infections (2%)